This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Fresenius Medical (FMS) Sinks on Potential Rise in Competition
by Zacks Equity Research
Fresenius Medical's (FMS) shares decline more than 17% on Wednesday following news of the successful clinical trial of a competing drug in preventing kidney disease.
Here's Why You Should Retain Fresenius Medical (FMS) for Now
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
Are Options Traders Betting on a Big Move in Fresenius Medical Care (FMS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Fresenius Medical Care (FMS) stock based on the movements in the options market lately.
Fresenius Medical's (FMS) New HHD Device to Increase Portability
by Zacks Equity Research
Fresenius Medical (FMS) gets FDA clearance for Versi HD with GuideMe Software, a portable, home hemodialysis device with an easy-to-use graphical interface providing easier training experiences.
Fresenius Medical (FMS) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Fresenius Medical's (FMS) second-quarter revenues benefit from strong performance across all segments. Inflationary pressure continues to improve, benefiting operating income.
Medical Device Aug 2 Earnings Roster: MCK, FMS & GKOS
by Indrajit Bandyopadhyay
Medical Device players are expected to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how MCK, FMS and GKOS are likely to have performed this time.
Fresenius Medical (FMS) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Fresenius Medical's (FMS) first-quarter revenues benefit from strong performances across all segments, especially the North America and Asia-Pacific regions. However, rising costs hurt margins.
Fresenius Medical's (FMS) Q4 Earnings and Revenues Beat
by Zacks Equity Research
Fresenius Medical's (FMS) fourth-quarter revenues benefit from strong performance across all segments, especially in the North America and Asia-Pacific regions. However, rising costs hurt margins.
MedTech Stocks' Q4 Earnings on Feb 22: FMS, GKOS & More
by Debanjana Dey
MedTech companies' Q4 results are likely to reflect strength in customer demand. Let's see how FMS, GKOS, MMSI and DVA are placed ahead of their earnings releases.
Why Is Nevro (NVRO) Up 14.9% Since Last Earnings Report?
by Zacks Equity Research
Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Douglas Dynamics and Fresenius Medical have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Douglas Dynamics and Fresenius Medical have been highlighted as Zacks Bull and Bear of the Day.
Bear of the Day: Fresenius Medical (FMS)
by David Bartosiak
Profit estimates are moving in the wrong direction.
Fresenius Medical's (FMS) Q3 Earnings and Revenues Top
by Zacks Equity Research
Fresenius Medical's (FMS) third-quarter revenues benefit from strong performance across all the geographic regions and segments. However, rising costs hurt margins.
Fresenius Medical (FMS) Robust Product Portfolio Drives Growth
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
Fresenius Medical's (FMS) Q2 Earnings Miss, Revenues Top
by Zacks Equity Research
Fresenius Medical's (FMS) second-quarter earnings benefit from strong performance across all the geographic regions and segments. However, rising costs hurt margins.
After Plunging 11.8% in 4 Weeks, Here's Why the Trend Might Reverse for Fresenius (FMS)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Fresenius (FMS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Here's Why You Should Retain Fresenius Medical (FMS) Stock Now
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
Fresenius (FMS) Faces Fraud Accusation From US Government
by Zacks Equity Research
The Department of Justice of the U.S. government files a civil complaint against Fresenius (FMS), accusing it of defrauding Medicare and other healthcare programs by billing for unnecessary procedures.
Here's Why You Should Retain Fresenius Medical (FMS) Stock Now
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
Fresenius Medical (FMS) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Fresenius Medical's (FMS) first-quarter earnings benefit from strong performance across all the geographic regions and segments.
Fresenius Medical (FMS) Launches Campaign to Boost Kidney Care
by Zacks Equity Research
Fresenius Medical's (FMS) My Reason campaign will help scientists understand genetic variations in patients with chronic kidney disease in a better way.
Fresenius Medical's (FMS) Merger Deal to Improve Kidney Care
by Zacks Equity Research
Fresenius Medical's (FMS) merger deal to build an independent entity to transform kidney care and health equity throughout the United States.
Fresenius Medical (FMS) Q4 Earnings Beat Estimates, Up Y/Y
by Zacks Equity Research
Fresenius Medical's (FMS) fourth-quarter earnings benefit from strong performance across all the geographic regions and segments.
Fresenius Medical's (FMS) New Dialyzer to Boost Patient Outcome
by Zacks Equity Research
Fresenius Medical's (FMS) latest dialyzer is expected to better serve dialysis patients because of its design.
Fresenius Medical (FMS) Q3 Earnings Beat Estimates, Down Y/Y
by Zacks Equity Research
Fresenius Medical's (FMS) third-quarter earnings benefit from strong performance across the regions, Asia Pacific and Latin America.